November_New Drugs｜New Breakthrough in Fertilizers, GLP-1 Wave Leads to Hundreds of Billions of Dollars in Business Opportunities

New Breakthrough in Weight Loss Drugs, Reducing Cardiovascular Disease Becomes a New Highlight of New Weight Loss Drugs

In the face value economy, when you want to stay slim while enjoying good food, you need God's rescue! According to 2023 World Obesity Atlas, obesity has been on the rise in the past few decades, and obesity is associated with heart disease, type 2 diabetes, and certain specific cancers, which makes obesity even more deadly! GLP-1 (glucagon-like peptide-1), the most important enterokinin in the human body, was originally injected subcutaneously as a new drug for diabetes. When you eat, the human digestive tract will release GLP-1 when stimulated by nutrients. GLP-1 will be released from the intestinal cells of the human digestive tract, which not only acts on the pancreas and liver, prompting the body to secrete more insulin and reduce glucagon, participating in blood glucose regulation to keep blood glucose stable, but also increase the central cerebral appetite suppression, sending satiety signals to the brain to reduce caloric intake and achieve weight loss and weight control, but also acts on the cardiovascular system to reduce inflammation by metabolism, to regulate blood pressure, blood lipids and thus improve cardiovascular function. Improve cardiovascular function. With Wegovy^®(Semaglutide) after five years of enrollment of 17,600 adults with a diagnosis of cardiovascular disease, overweight or obese without a history of diabetes, the results of a large-scale pivotal clinical trial report, the results show that Semaglutide can reduce the risk of serious cardiovascular disease, such as cardiovascular disease and stroke as much as 20%, lowering cardiovascular disease is like a new point of attraction for the new drug to reduce weight, the new drug is not only expanding the approved indications and expanding the use rate, but also adding to the sales prospects of the drug. Semaglutide's multiple effects of lowering glucose, reducing weight and lowering cardiovascular disease will not only expand the approved indications and the utilization rate of the drug, but also increase the prospects of the drug sales market.